New products carry ClearStream through strong H1
This article was originally published in Clinica
Irish angioplasty products developer ClearStream Technologies reported a near three-fold increase in turnover for the first half of fiscal 2007, thanks to the successful uptake of several recently-launched niche products such as the Nimbus Pico catheter and the ReeKross catheter for treating critical limb ischaemia.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.